One to Watch: Expanded HyBryte Treatment Produces Positive Outcomes in Early-Stage CTCL
Extended HyBryte treatment for up to 12 months is showing promise in patients with early-stage cutaneous T-cell lymphoma (CTCL), according to an interim update from an open-label, investigator-initiated study (IIS). Soligenix, Inc.’s HyBryte (research name SGX301) is a novel, first-in-class photodynamic therapy that utilizes safe, visible light for activation. The active ingredient in HyBryte is synthetic hypericin, […]